Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone510-871-4188
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees76
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Frequently Asked Questions
What is Lineage Cell Therapeutics' stock symbol?
Lineage Cell Therapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "LCTX."
When is Lineage Cell Therapeutics' next earnings date?
What price target have analysts set for LCTX?
3 brokers have issued twelve-month price objectives for Lineage Cell Therapeutics' shares. Their forecasts range from $3.00 to $4.00. On average, they anticipate Lineage Cell Therapeutics' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 348.7% from the stock's current price. View Analyst Price Targets for Lineage Cell Therapeutics.
What is the consensus analysts' recommendation for Lineage Cell Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lineage Cell Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lineage Cell Therapeutics.
Has Lineage Cell Therapeutics been receiving favorable news coverage?
News articles about LCTX stock have trended somewhat positive recently, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Lineage Cell Therapeutics earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Lineage Cell Therapeutics.
Are investors shorting Lineage Cell Therapeutics?
Lineage Cell Therapeutics saw a decline in short interest in the month of October. As of October 31st, there was short interest totalling 5,880,000 shares, a decline of 5.0% from the September 30th total of 6,190,000 shares. Based on an average daily volume of 374,500 shares, the days-to-cover ratio is presently 15.7 days. Approximately 4.0% of the company's stock are short sold. View Lineage Cell Therapeutics' Current Options Chain.
Who are some of Lineage Cell Therapeutics' key competitors?
Some companies that are related to Lineage Cell Therapeutics include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), Apotheca Biosciences (CBDC), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Biocure Technology (CURE), Canada House Wellness Group (CHV), Cannabics Pharmaceuticals (CNBX), CannaRoyalty (ORHOF), Cardiome Pharma (COM), China Longyi Group Int'l (CGYG), Creative Medical Technology (CELZ) and Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs (CYCCP).
What other stocks do shareholders of Lineage Cell Therapeutics own?
Who are Lineage Cell Therapeutics' key executives?
Lineage Cell Therapeutics' management team includes the folowing people:
- Mr. Brian M. Culley, CEO, Pres & Director (Age 48)
- Ms. Brandi L. Roberts, Chief Financial Officer (Age 45)
- Ioana C. Hone, Director of Investor Relations
- Mr. Chase C. Leavitt, Gen. Counsel & Corp. Sec. (Age 37)
- Mr. James Knight, Sr. VP & Head of Corp. Devel.
Who are Lineage Cell Therapeutics' major shareholders?
Lineage Cell Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Defender Capital LLC. (2.54%), Creative Planning (0.14%), Rhumbline Advisers (0.12%), Commonwealth Equity Services LLC (0.08%), California Public Employees Retirement System (0.03%) and Moors & Cabot Inc. (0.02%). Company insiders that own Lineage Cell Therapeutics stock include Brian M Culley, Broadwood Partners, LP and Chase C Leavitt. View Institutional Ownership Trends for Lineage Cell Therapeutics.
Which institutional investors are buying Lineage Cell Therapeutics stock?
LCTX stock was acquired by a variety of institutional investors in the last quarter, including Defender Capital LLC., Creative Planning, Rhumbline Advisers, Commonwealth Equity Services LLC, California Public Employees Retirement System and Moors & Cabot Inc.. Company insiders that have bought Lineage Cell Therapeutics stock in the last two years include Brian M Culley, Broadwood Partners, LP and Chase C Leavitt. View Insider Buying and Selling for Lineage Cell Therapeutics.
How do I buy shares of Lineage Cell Therapeutics?
Shares of LCTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Lineage Cell Therapeutics' stock price today?
One share of LCTX stock can currently be purchased for approximately $0.78.
How big of a company is Lineage Cell Therapeutics?
What is Lineage Cell Therapeutics' official website?
How can I contact Lineage Cell Therapeutics?
The company can be reached via phone at 510-871-4188.
MarketBeat Community Rating for Lineage Cell Therapeutics (NYSEAMERICAN LCTX)
MarketBeat's community ratings are surveys of what our community members think about Lineage Cell Therapeutics and other stocks. Vote "Outperform" if you believe LCTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LCTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
